In order to be eligible to participate in this study, a patient must meet all of the following inclusion criteria: 1. Adult ≥18 years of age at the time of enrolment 2. Hospitalized patients with any of the following criteria: a. the presence of pulmonary rales/crackles on clinical exam OR b. SpO2 ≤ 94% on room air OR c. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation 3. A time between onset of symptoms and randomization of less than 9 days 4. A positive SARS-CoV-2 PCR performed on a NP swab within the 5 days preceding randomization 5. The result of a rapid antigen test performed on a NP swab within the 6 hours preceding randomization 6. Contraceptive use by men or women. a. Male participants: Contraception for male participants is not required, however, to avoid the transfer of any fluids, all male participants must use a condom from Day 1 and agree to continue for 90 days following administration of IMP. b. Female participants: Women of child-bearing potential must agree to use contraception for 365 days following administration of IMP. Acceptable birth control methods are listed in section 8.5.

In order to be eligible to participate in this study, a patient must meet all of the following inclusion criteria: 1. Adult ≥18 years of age at the time of enrolment 2. Hospitalized patients with any of the following criteria: a. the presence of pulmonary rales/crackles on clinical exam OR b. SpO2 ≤ 94% on room air OR c. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation 3. A time between onset of symptoms and randomization of less than 9 days 4. A positive SARS-CoV-2 PCR performed on a NP swab within the 5 days preceding randomization 5. The result of a rapid antigen test performed on a NP swab within the 6 hours preceding randomization 6. Contraceptive use by men or women. a. Male participants: Contraception for male participants is not required, however, to avoid the transfer of any fluids, all male participants must use a condom from Day 1 and agree to continue for 90 days following administration of IMP. b. Female participants: Women of child-bearing potential must agree to use contraception for 365 days following administration of IMP. Acceptable birth control methods are listed in section 8.5.

In order to be eligible to participate in this study, a patient must meet all of the following inclusion criteria: 1. Adult ≥18 years of age at the time of enrolment 2. Hospitalized patients with any of the following criteria: a. the presence of pulmonary rales/crackles on clinical exam OR b. SpO2 ≤ 94% on room air OR c. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation 3. A time between onset of symptoms and randomization of less than 11 days 4. A positive SARS-CoV-2 PCR performed on a NP swab within the 5 days preceding randomization 5. The result of a rapid antigen test performed on a NP swab within the 6 hours preceding randomization 6. Contraceptive use by men or women. a. Male participants: Contraception for male participants is required. To avoid the transfer of any fluids, all male participants must use a condom from Day 1 and agree to continue for 90 days following administration of IMP. b. Female participants: Women of child-bearing potential must agree to use contraception for 365 days following administration of IMP. Acceptable birth control methods are listed in section 8.5.

In order to be eligible to participate in this study, a patient must meet all of the following inclusion criteria: 1. Adult ≥18 years of age at the time of enrolment 2. Hospitalized patients with any of the following criteria: a. the presence of pulmonary rales/crackles on clinical exam OR b. SpO2 ≤ 94% on room air OR c. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation 3. A time between onset of symptoms and randomization of less than 11 days 4. A positive SARS-CoV-2 PCR performed on a NP swab within the 5 days preceding randomization 5. The result of a rapid antigen test performed on a NP swab within the 6 hours preceding randomization 6. Contraceptive use by men or women. a. Male participants: Contraception for male participants is required. To avoid the transfer of any fluids, all male participants must use a condom from Day 1 and agree to continue for 90 days following administration of IMP. b. Female participants: Women of child-bearing potential must agree to use contraception for 365 days following administration of IMP. Acceptable birth control methods are listed in section 8.5.

In order to be eligible to participate in this study, a patient must meet all of the following inclusion criteria: 1. Adult ≥18 years of age at the time of enrolment 2. Hospitalized patients with any of the following criteria: a. the presence of pulmonary rales/crackles on clinical exam OR b. SpO2 ≤ 94% on room air OR c. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation 3. A time between onset of symptoms and randomization of less than 9 days 4. A positive SARS-CoV-2 PCR performed on a NP swab within the 5 days preceding randomization 5. The result of a rapid antigen test performed on a NP swab within the 6 hours preceding randomization 6. Contraceptive use by men or women. a. Male participants: Contraception for male participants is not required, however, to avoid the transfer of any fluids, all male participants must use a condom from Day 1 and agree to continue for 90 days following administration of IMP. b. Female participants: Women of child-bearing potential must agree to use contraception for 365 days following administration of IMP. Acceptable birth control methods are listed in section 8.5.

In order to be eligible to participate in this study, a patient must meet all of the following inclusion criteria: 1. Adult ≥18 years of age at the time of enrolment 2. Hospitalized patients with any of the following criteria: a. the presence of pulmonary rales/crackles on clinical exam OR b. SpO2 ≤ 94% on room air OR c. requirement of supplementary oxygen including high flow oxygen devices or non-invasive ventilation 3. A time between onset of symptoms and randomization of less than 9 days 4. A positive SARS-CoV-2 PCR performed on a NP swab within the 5 days preceding randomization 5. The result of a rapid antigen test performed on a NP swab within the 6 hours preceding randomization 6. Contraceptive use by men or women. a. Male participants: Contraception for male participants is not required, however, to avoid the transfer of any fluids, all male participants must use a condom from Day 1 and agree to continue for 90 days following administration of IMP. b. Female participants: Women of child-bearing potential must agree to use contraception for 365 days following administration of IMP. Acceptable birth control methods are listed in section 8.5.